Made In USAFor Laboratory Research OnlyCOAs Not Yet AvailableExplore Compound Research ProfilesCompare Catalog SizesResearch Requests Reviewed IndividuallyNot For Human Or Veterinary Use
Research blend

KLOW

Catalog size
$129
USD per vial · 80 mgCatalog price
Research only

KLOW lists GHK-Cu, BPC-157, TB-500 and KPV, connecting component studies of skin-matrix remodeling, cell migration and intestinal inflammatory signaling.

Explore the research profile

Submit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.

No reservation or purchase is made by adding a material.
View documentation status ← Back to collection
Listed components
GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV (amount pending)
Format
Awaiting confirmation
Availability
Confirmed during review

Catalog quantities are not assay results.

In the literature

The components. The research context.

Four-component matrix and inflammatory-signaling research blend

Understanding the formulation

KLOW is a four-component catalog formulation, rather than a defined endogenous peptide. It extends the GHK-Cu, BPC-157 and TB-500 grouping with KPV, the lysine-proline-valine sequence associated with alpha-MSH research. The retained catalog label is 80 mg, but the KPV amount is not yet confirmed. It should not be calculated by subtracting the other listed quantities from the label total.

Reference identity
Research class
Four-component matrix and inflammatory-signaling research blend
Catalog search names
GHK-Cu TB-500 BPC-157 KPV

This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.

Why these components are studied

GHK-Cu experiments investigate remodeling of extracellular matrix, the supporting material surrounding cells, while BPC-157 work tests movement and survival of tendon-derived cells. KPV studies examine how peptide uptake influences inflammatory signaling in intestinal and immune cells. These are distinct aspects of tissue biology. The TB-500 sequence must be confirmed before selecting the relevant thymosin literature, and separate component studies do not establish how the four ingredients behave together.

Component and related research

These links provide research context; they do not confirm the exact materials in this formulation.

Documented lines of inquiry

Research areas

  1. 01

    Extracellular-matrix turnover

    Cultured dermal fibroblasts showed increased MMP-2 and secretion of its tissue inhibitors after GHK-Cu exposure. These measurements concern turnover of the matrix around skin cells. Copper alone reproduced the MMP-2 response, so that finding does not establish an effect unique to the intact peptide-copper complex. [1]

  2. 02

    Intestinal inflammatory signaling

    KPV entered intestinal epithelial and immune cells through the peptide transporter PepT1 and reduced inflammatory NF-kappaB and MAP kinase signaling in the tested systems. Mouse colitis experiments provided additional preclinical context. These findings do not establish digestive or skin benefits from KLOW. [2]

  3. 03

    Repair-associated cell behavior

    BPC-157 studies provide a separate line of inquiry into tendon-derived cell migration and survival. They do not establish interaction with KPV, copper complexes or a TB-500 component. [3]

Study topics describe the cited models, not established benefits of this catalog material.

Reading the evidence

What the studies
can tell us.

Component evidence · finished blend untested in cited studies

The linked publications describe component-level experiments. The selected literature does not test a finished KLOW vial, its four-way combination or the listed formulation. Its biological interpretation remains limited by both the absence of direct blend evidence and the incomplete quantity and identity specifications.

What remains uncertain

The unconfirmed KPV amount prevents an exact formulation comparison. Full-length thymosin beta-4 findings should not be assigned to unspecified TB-500. Any assessment of mixture stability, component recovery or analytical purity needs formulation-specific documentation; none can be established by combining summaries from separate papers.

Read the source

Selected literature

These papers concern individual components or related molecules. They do not validate this finished blend.

  1. 01PubMed
  2. 02
    2008 · Cell and animal study

    PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (opens a new tab)

    PepT1 uptake and inflammatory signaling in cell systems, with mouse colitis experiments.

    PubMed
  3. 03PubMed

Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.

Before you begin

The details behind
the material.

Specifications and storage

Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.

Research use only

For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.

What to look for in a COA
Before you explore

Laboratory
research only.

Please confirm the following to enter the Wyz Labs collection.

Select both confirmations to continue.

Your acknowledgment is remembered for this browser session. This is a self-declaration, not identity verification.